California State Teachers Retirement System Acquires 69,434,598 Shares of Becton, Dickinson and Company $BDX

Key Points

• California State Teachers Retirement System increased its Becton, Dickinson and Company stake by 14,668.6%, acquiring 69.4 million additional shares and bringing its ownership to 25.37%, worth approximately $10.6 billion.
• Becton, Dickinson exceeded quarterly expectations, reporting $3.23 in EPS and $4.98 billion in revenue, while revenue grew 5.4% year over year. The company maintained FY 2026 EPS guidance of $12.62–$12.72.
• BDX shares opened at $179.35, with analysts holding a consensus “Hold” rating and an average price target of $187.67. The company also announced a quarterly dividend of $1.05 per share, representing a 2.3% annualized yield.

California State Teachers Retirement System boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14,668.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,907,953 shares of the medical instruments supplier's stock after acquiring an additional 69,434,598 shares during the period. California State Teachers Retirement System owned 25.37% of Becton, Dickinson and Company worth $10,579,171,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in BDX. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth about $3,721,533,000. Wellington Management Group LLP grew its stake in Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock valued at $769,397,000 after acquiring an additional 4,137,888 shares during the period. Finally, Norges Bank bought a new position in Becton, Dickinson and Company in the 4th quarter valued at about $734,321,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,005 shares of company stock valued at $1,423,580. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Stock Down 2.9%

Shares of BDX opened at $179.35 on Wednesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07. The firm's 50 day moving average is $171.21 and its 200-day moving average is $160.61. The stock has a market capitalization of $49.42 billion, a PE ratio of 54.02, a P/E/G ratio of 13.02 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is presently 126.51%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BDX shares. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a report on Thursday, August 13th. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 27th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. Piper Sandler boosted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Finally, TD Cowen upped their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $187.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.